Hoth Therapeutics Faces Delisting Concerns
Ticker: HOTH · Form: 8-K · Filed: May 16, 2025 · CIK: 1711786
| Field | Detail |
|---|---|
| Company | Hoth Therapeutics, Inc. (HOTH) |
| Form Type | 8-K |
| Filed Date | May 16, 2025 |
| Risk Level | high |
| Sentiment | bearish |
Sentiment: bearish
Topics: delisting, compliance, regulatory
TL;DR
Hoth Therapeutics might get delisted - big trouble ahead.
AI Summary
Hoth Therapeutics, Inc. filed an 8-K on May 16, 2025, reporting a notice of delisting or failure to satisfy continued listing rules. The filing indicates potential issues with maintaining its listing on the stock exchange.
Why It Matters
This filing signals potential financial distress or non-compliance with exchange rules, which could lead to the company's stock being removed from trading.
Risk Assessment
Risk Level: high — A notice of delisting directly threatens the company's ability to remain publicly traded, posing a significant risk to investors.
Key Players & Entities
- Hoth Therapeutics, Inc. (company) — Registrant
- May 13, 2025 (date) — Date of earliest event reported
- May 16, 2025 (date) — Date of Report
- Nevada (jurisdiction) — State of incorporation
- 001-38803 (identifier) — Commission File Number
- 82-1553794 (identifier) — I. R. S. Employer Identification No.
- 1177 Avenue of the Americas, 5th Floor, Suite 5066 New York, NY 10036 (address) — Address of principal executive offices
- (646) 756-2997 (phone_number) — Registrant's telephone number
FAQ
What specific listing rule or standard has Hoth Therapeutics, Inc. failed to satisfy?
The filing does not specify the exact rule or standard that Hoth Therapeutics, Inc. has failed to satisfy, only that a notice of delisting or failure to satisfy a continued listing rule or standard has been issued.
What is the date of the earliest event reported in this 8-K filing?
The date of the earliest event reported is May 13, 2025.
What is the company's state of incorporation?
Hoth Therapeutics, Inc. is incorporated in Nevada.
What is the company's principal executive office address?
The principal executive offices are located at 1177 Avenue of the Americas, 5th Floor, Suite 5066, New York, NY 10036.
What is the purpose of this Form 8-K filing?
This Form 8-K is filed to report a notice of delisting or failure to satisfy a continued listing rule or standard.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on May 16, 2025 regarding Hoth Therapeutics, Inc. (HOTH).